BDSX vs. GRAL, FLGT, AUNA, INNV, TALK, DCGO, CELC, EHAB, PSNL, and VMD
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Grail (GRAL), Fulgent Genetics (FLGT), Auna (AUNA), InnovAge (INNV), Talkspace (TALK), DocGo (DCGO), Celcuity (CELC), Enhabit (EHAB), Personalis (PSNL), and Viemed Healthcare (VMD). These companies are all part of the "healthcare" industry.
Biodesix vs.
Biodesix (NASDAQ:BDSX) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking.
Grail has a net margin of 0.00% compared to Biodesix's net margin of -66.84%. Grail's return on equity of 0.00% beat Biodesix's return on equity.
In the previous week, Grail had 9 more articles in the media than Biodesix. MarketBeat recorded 10 mentions for Grail and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.45 beat Grail's score of 0.28 indicating that Biodesix is being referred to more favorably in the media.
Grail has lower revenue, but higher earnings than Biodesix.
Biodesix presently has a consensus target price of $3.06, suggesting a potential upside of 166.09%. Grail has a consensus target price of $16.00, suggesting a potential downside of 8.15%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Grail.
21.0% of Biodesix shares are held by institutional investors. 69.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Biodesix received 29 more outperform votes than Grail when rated by MarketBeat users. Likewise, 74.36% of users gave Biodesix an outperform vote while only 0.00% of users gave Grail an outperform vote.
Summary
Biodesix beats Grail on 9 of the 13 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 1/20/2025 by MarketBeat.com Staff
